Status:
COMPLETED
Role of Cysteinyl Leukotrienes in the Pathogenesis of Asthma in Obesity
Lead Sponsor:
University of Michigan
Collaborating Sponsors:
Merck Sharp & Dohme LLC
Conditions:
Asthma
Obesity
Eligibility:
All Genders
18-65 years
Brief Summary
The purpose of this study is to examine whether there are higher levels of cysteinyl leukotrienes in obese subjects than in non-obese subjects. Cysteinyl leukotrienes are pro-inflammatory substances t...
Detailed Description
This is a cross-sectional observational study to characterize the association between obese asthmatics and the inflammatory mediators cysteinyl leukotrienes. Our hypothesis is that altered adipokine l...
Eligibility Criteria
Inclusion
- 18-65 yr old adults with asthma, non-smoking for at least one year
- Healthy non-smoking adults, aged 18-65 without asthma
- Heavy subjects with BMI \> 30 kg/m2
- Subjects with normal weight (BMI between 20-25 kg/m2)
- Subject not taking anti-leukotriene therapy (Singulair, Accolate, Zyflo)
Exclusion
- No chronic oral steroid use
- No recent history of infection
- No recent history of flare of lung disease
Key Trial Info
Start Date :
July 1 2010
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
May 1 2013
Estimated Enrollment :
117 Patients enrolled
Trial Details
Trial ID
NCT01158573
Start Date
July 1 2010
End Date
May 1 2013
Last Update
January 24 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Michigan
Ann Arbor, Michigan, United States, 48109